Author Affiliations: Department of Psychological Medicine, Institute of Psychiatry, London, England.
The selective serotonin reuptake inhibitors (SSRIs) were a welcome innovation
in the treatment of depression. Although these drugs are no more efficacious
than their predecessors, they are safer in overdose and more acceptable in
terms of adverse effects.1 The popularity of
the SSRIs in general, and of fluoxetine (Prozac) in particular, created its
own problems. For instance, Prozac achieved a recognition normally given to
household items in which the brand name has become identified with the generic
Wessely S, Kerwin R. Suicide Risk and the SSRIs. JAMA. 2004;292(3):379–381. doi:10.1001/jama.292.3.379
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: